CYTOTOXIC EFFECT OF 15d-PGJ2 AGAINST UTERINE SALCOMA by Kawakita, Takako et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE  13:  2939-2945,  2017
Abstract. Effective chemotherapeutic strategies for uterine 
sarcoma are lacking; existing therapies achieve poor response 
rates. Previous studies have identified the prostaglandin 
15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2) as a potential 
anticancer treatment; however, its effectiveness in uterine 
sarcoma has not been examined. Furthermore, the molecular 
mechanisms underlying the cytotoxic mechanism of 15d-PGJ2 
remain unclear. Here, we evaluated the effects of 15d-PGJ2 
alone and in combination with the tyrosine kinas inhibitor 
(TKI) dasatinib in uterine sarcoma cell lines (MES-SA, 
MES-SA/DX5 and SKN). 15d-PGJ2 inhibited cell growth 
and increased apoptosis. Western blotting demonstrated that 
15d-PGJ2 treatment increased MEK and ERK phosphoryla-
tion, and decreased levels of phosphorylated AKT. Dasatinib 
in combination with 15d-PGJ2 significantly reduced cell 
proliferation compared with 15d-PGJ2 alone, and repressed 
both the AKT and MAPK pathways. The cell growth inhibi-
tion rate in the PGJ2 was 21.5±12.0, 35.3±5.4 and 28.3±4.2%, 
respectively (MES-SA, MES-SA/DX5 and SKN cell lines) 
and the cell growth inhibition rate in the combination therapy 
was significantly higher compared with 15d-PGJ2 alone 
(MES-SA; 64.2±0.8, MES-SA/DX5;23.9±8.2 and SKN; 
41.4±17.6%). The PGJ2 IC50 determined by MTT assay 
was 27.41,10.46 and 17.38 µmol/l, respectively (MES-SA, 
MES-SA/DX5 and SKN cell lines) and the dasatinib IC50 
was 6.68,17.30 and 6.25 µmol/l, respectively. Our findings 
demonstrate that 15d-PGJ2 suppresses proliferation by inac-
tivating the AKT pathway in uterine sarcoma. Furthermore, 
combining 15d-PGJ2 with dasatinib produced a synergistic 
effect on cancer cell inhibition by repressing 15d-PGJ2-medi-
ated activation of MAPK signaling, and further repressing 
AKT signaling. These results suggest that 15d-PGJ2 could be 
used in combination with dasatinib as a potential therapeutic 
approach for uterine sarcoma.
Introduction
Uterine sarcoma is associated with aggressive characteristics 
and poor clinical outcome. The most effective treatment for 
this disease is a complete resection of the primary lesion at an 
early stage. However, if surgical remission cannot be achieved, 
the clinical outcome is poor. When postoperative chemo-
therapy is selected for uterine carcinosarcoma, regimens 
include ifosfamide, platinum-based drugs, and paclitaxel (1). 
However, in uterine leiomyosarcoma, chemotherapy only 
achieves a 30% response rate (2). Standard therapies have 
not been established due to difficulties with early diagnosis 
and drug-resistant phenotypes. Thus, the development of new 
therapeutic approaches is necessary to treat this disease.
15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2, Fig. 1) is 
a type of prostaglandin (PG). PGs are produced from cyclo-
oxygenase-2 (Cox-2) enzyme oxidation of arachidonic acid in 
response to various stress stimulations. Previous studies have 
shown that 15d‑PGJ2 significantly inhibits cell growth and 
induces apoptosis in cancer cells, indicating it as a potential 
cancer treatment (3,4). 15d-PGJ2 induces a variety of cellular 
responses including activation of mitogen-activated protein 
kinase (MAPK) (5), modulation of Cox-2 (6), inhibition of 
vascular smooth muscle cell proliferation and upregulation 
of antioxidant response genes (7). In osteosarcoma and other 
cancers, 15d-PGJ2 has been demonstrated to inhibit cancer 
cell growth (8,9). However, its role in uterine sarcoma has not 
been reported.
Peroxisome proliferator-activated receptors (PPAR) ο, β 
and γ are nuclear hormone receptors that regulate a multi-
tude of downstream metabolic processes (10). In particular, 
PPAR-γ plays a variety of roles in antiproliferation, proapop-
totic and antiangiogenic pathways (5,9-11). Numerous studies 
have demonstrated that PPAR-γ ligands exert antiproliferative 
effects in several cancers, including breast (4), prostate (12,13), 
and colon cancer (14,15). PPAR-γ ligands include endogenous 
ligands such as the eicosanoid cascade and 15d-PGJ2. PPAR-γ 
agonists have shown anti-cancer activity both in vitro and 
in vivo in combination with conventional anticancer drugs 
including platinum-based drugs (16), taxanes (17,18), and 
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irinotecan (17). However, the pathways affected by treatment 
with PPAR-γ agonists and the most suitable combination 
therapy based on theoretical signaling mechanisms remain 
unclear.
A previous study showed inhibition of uterine sarcoma 
cell growth by suppression of tyrosine kinase (19). Dasatinib 
(V. 1) is an orally available tyrosine kinase inhibitor (TKI) 
that inhibits SRC protein. This drug is currently being exam-
ined in patients with acute myeloid leukemia and chronic 
lymphocytic leukemia (20,21) and also in several solid 
tumors (18,22).
In this study, we evaluated the possibility of combination 
therapy of PGJ2 and dasatinib in the treatment of uterine 
sarcoma. The results of this study may provide a novel thera-
peutic strategy for treatment of uterine sarcoma.
Materials and methods
Cell lines. The human uterine sarcoma cell lines MES-SA 
and MES-SA/DX5 and human uterine leiomyosarcoma cell 
line SKN were purchased from the European Collection of 
Cell Cultures (Salisbury, Wiltshire UK) and the Japan Health 
Science Foundation (Osaka, Japan), respectively. MES-SA and 
MES-SA/DX5 cells were cultured in McCoy medium whereas 
SKN cells were maintained in Ham's F12 medium supple-
mented with 10% fetal bovine serum, penicillin (100 U/ml), 
and streptomycin (100 µ/ml) at 37˚C in 5% CO2.
Reagents. PJ2 was purchased from Santa Cruz Biotechnology, 
Inc. (Santa Cruz, CA, USA). Dasatinib was obtained from Focus 
Biomolecules (Plymouth Meeting, PA, USA) and dissolved 
in DMSO with a final concentration of 0.05% in the culture 
medium. MEK and phospho-MEK (ser217/221) antibodies 
were purchased from Santa Cruz Biotechnology, Inc., and SRC, 
phospho-SRC (tyr416), ERK, phospho-ERK (tyr204), AKT, 
phospho-AKT and β-actin antibodies were purchased from Cell 
Signaling Technology, Inc. (Beverly, MA, USA).
In vitro analyses of cell proliferation and apoptosis. 
Cells were seeded in 96-well culture plates at a density of 
1.0x104 cells/well in a volume of 100 µl. At 24 h later, PGJ2, 
dasatinib or PGJ2+dasatinb were added at various concentrations 
and cells were incubated overnight. Next, 10 µl of 2-(4-iodoph
enyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium 
monosodium salt solution (WST1; Roche Diagnostics GmbH, 
Mannheim Germany) was added to the wells and the plates ware 
incubated for additional 2 h at 37˚C. Absorbance at 450 nm was 
measured by a plate reader.
To measure cellular apoptosis, quantitative caspase-3/7 
enzyme assay (Promega Corp., Madison, WI, USA) was 
performed. Apoptosis was also assayed by detecting DNA 
fragmentation using in situ terminal deoxynucleotidyl trans-
ferase-mediated dUTP nick end-labeling (TUNEL) (Promega 
Corp.). Cells treated with DNaseI (Promega Corp.) were used as 
positive controls.
Immunoblotting. Cells were collected on ice, washed with 
PBS, and lysed with 1x cell lysis buffer (Thermo Scientific 
Pierce; Life Technologies, Carlsbad, CA, USA), adding 2.5 µl 
protease inhibitor (WAKO, Osaka, Japan) immediately before 
use. Cell lysate was collected after centrifugation (12,000 rpm, 
10 min) and protein concentration was determined using the 
Pearce BSA protein assay kit (Thermo Scientific Pierce). Equal 
amounts of protein samples were separated by SDS-PAGE on 
7.5% acrylamide minigels and transferred to a nitrocellulose 
membrane. After incubation in 3% BSA blocking buffer for 
2 h, the membrane was treated with one of the primary anti-
bodies, followed by the respective secondary antibodies. The 
signal was detected by an ECLPlus system (GE Healthcare, 
Buckinghamshire, England, UK). We reprobed the membrane 
after incubation in 15 ml stripping buffer (Takara Bio Inc., 
Kusatsu, Japan) for 1 h at room temperature. The band intensities 
were quantified using the ImageJ software program [National 
Institutes of Health (NIH), Bethesda, MA, USA].
Analysis of drug synergism. The combination index (CI) was 
calculated for the analysis of the synergistic, antagonistic or 
additive effects of the two drugs. CompuSyn program (Chou and 
Martin) was used to compute a CI for drug combinations studied 
with growth assays. The Chou-Talalay combination-index 
method for drug combination is based on the median-effect 
equation which is the unified theory that provides the common 
link between single entity and multiple entities (23) CI>1 indi-
cates antagonism, CI=1 indicates an additive effect and CI<1 
indicates synergy.
Statistical analysis. Data shown are means ± SEM. Significant 
differences were determined by applying Student's t-test or 
ANOVA with Bonferroni's adjustment as appropriate. P<0.05 
was considered to indicate a statistically significant difference.
Figure 1. (A) Chemical structure of 15-deoxy-Δ12,14-prostaglandin J2. 
(B) Chemical structure of dasatinib.
Table I. Combination index.
Cell line ED50 ED75 ED90 ED95
MEA-SA 0.48970 0.33910 0.25557 0.22472
MES-SA/Dx5 0.36428 0.41357 0.49295 0.56954
SKN 0.36301 0.35493 0.36386 0.37558
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Results
PGJ2 inhibits sarcoma cell growth and increases apoptosis. 
To evaluate the effect of 15d-PGJ2 on the growth of uterine 
sarcoma cells, we used the drug sensitive human sarcoma cell 
line MES-SA, its multidrug resistant counterpart MES-SA/Dx5 
and the uterine leiomyosarcoma cell line SKN for experimental 
analyses. Cells were treated with various concentrations of 
15d-PGJ2 (1, 5, 10, 20 and 50 µmol/l) for 24 h and examined 
by WST1 assay (Fig. 2A‑C). We detected a significant reduction 
in cell growth starting at 10 µmol/l 15d-PGJ2 in all of the cell 
lines.
We next examined the effects of 10 µmol/l 15d-PGJ2 on 
cell proliferation over time. We treated cells with 10 µmol/l 
15d-PGJ2 and incubated cells for various times (0, 3, 6, 12 or 
24 h) (Fig. 2D‑F). We detected a significant reduction in cell 
growth starting at 24 h treatment in all of the cell lines. Together 
our results showed that 15d‑PGJ2 significantly inhibited the 
growth of all three uterine sarcoma cell lines in a dose- and 
time-dependent manner.
We then investigated whether 15d-PGJ2 induced apoptosis of 
uterine sarcoma cell lines. We treated all three uterine sarcoma 
cell lines with 15d-PGJ2 at different dose levels and examined 
the effects on cellular apoptosis using the caspase-3/7 assay after 
12 h of culture (Fig. 3A-C) and by TUNEL assays (Fig. 3D). 
The results from both assays showed that 15d-PGJ2 treatment 
resulted in increased apoptosis. These studies indicated that 
15d-PGJ2 exerts a cytotoxic effect, inhibiting uterine sarcoma 
cell growth.
PGJ2 treatment activates the MAPK pathway. Previous studies 
showed that PGJ2 alters phosphorylation of PPAR-γ, suggesting 
that this compound might affect the activity of upstream kinases. 
Other reports demonstrated that 15-d-PGJ2 induced ERK acti-
vation (24,25). To test whether PGJ2 affects the MAPK pathway 
in uterine sarcoma cells, MES-SA and MES-SA/Dx5 cells were 
treated with various concentrations of PGJ2 for 24 h and total 
cell lysates were analyzed by western blot analysis (Fig. 3E). 
The western blot results showed that both MEK and ERK were 
phosphorylated in treated cells compared with controls (22). 
The AKT pathway is another important survival pathway. A 
previous study reported downregulation of the AKT pathway 
by antitumor inhibitors (26). The western blot results showed 
that phosphorylation of AKT was decreased by 15d-PGJ2 in 
uterine sarcoma cells, indicating that 15d-PGJ2 represses the 
AKT pathway.
In vitro effects of combination therapy with PGJ2 and dasatinib. 
Our results suggest that the antiproliferative effects of 15d-PGJ2 
were associated with inactivation of AKT. However the MAPK 
has been activated. We then speculated that combining drugs 
that suppressed AKT and MAPK would result in enhanced 
anti-tumor effects. We therefore used the TKI dasatinib to 
suppress MAPK signaling in combination with 15d-PGJ2.
Figure 2. 15d-PGJ2 inhibits the growth of uterine sarcoma cells. (A-C) MES-SA, MES-SA/DX5, and SKN cells were seeded 1 day before treatment with 
various concentrations of 15d-PGJ2 for 24 h or DMSO as control. Cell viability was assessed using WST1 assays and expressed as a percentage of viability 
under controlled culture conditions. (D-F) Cells were treated with 15d-PGJ2 (10 µmol/l) and incubated for various times. WST1 assays were performed and 
cell viability was determined. All data represent the mean ± SD of three independent experiments. *P<0.05.
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MES-SA cells were treated with 15d-PGJ2 (10 µmol/l) 
and various concentrations of dasatinb (1, 3, 5 and 10 µmol/l) 
for 24 h and examined by WST-1 assay (Fig. 4A-C). We also 
examined the effects of 10 µmol/l 15d-PGJ2 and 5 µmol/l 
dasatinb on cellular apoptosis using the caspase-3/7 assay after 
12 h of culture (Fig. 4D-F). The results showed that dasatinib in 
combination with 15d‑PGJ2 significantly reduced cell prolifera-
tion and increased apoptosis compared with 15d-PGJ2 alone in 
concentration dependent manners.
The CI was used to analyze the synergistic effect. The CI was 
0.489,0.36428 and 0.36301 in the MES-SA cell, MES-SA/DX5 
and SKN cell line, indicating that combined PGJ2 and dasatinib 
generates synergistic effect (Table I). We also found that the 
combination therapy induced a significant downregulation of 
AKT and MAPK pathways compared with treatment of either 
15d-PGJ2 or dasatinb alone (Fig. 4G). Our results showed that 
the combination therapy exerts antitumor effects with more 
pronounced compared with either treatment alone.
Discussion
PPAR-γ is targeted by endogenous ligands such as Δ12.15 
prostaglandin J2 and functions as a transcriptional factor 
in vivo (9,15). PPAR-γ plays a variety of roles in antiprolifera-
tion and proapoptotic pathways. In this study, our results showed 
that 15d-PGJ2 inhibited uterine sarcoma cell proliferation by 
inducing apoptosis. This finding is in agreement with the results 
of previous studies of 15d-PGJ2 in other cell lines (27). However, 
the molecular mechanisms underlying the cytotoxic mechanism 
of 15d-PGJ2-induced apoptosis remained unclear. The present 
study shows that 15d-PGJ2 induced downregulation of the AKT 
pathway with subsequent apoptosis.
In this study, we found that 15d-PGJ2 induced 
antiproliferative effects in uterine sarcoma cells. Two main 
survival signaling pathways, MAPK and AKT pathways are 
downregulated by antitumor inhibitors (26). Our results showed 
that 15d-PGJ2 inhibited phosphorylation of AKT and also 
Figure 3. 15d-PGJ2 induces apoptosis of uterine sarcoma cells and downregulates the AKT pathway. (A-C) Cellular apoptosis levels in MES-SA, MES-SA/DX5, 
and SKN cells treated with 15d‑PGJ2 (10 µmol/l) for 24 h were quantified using the caspase‑3/7 assay. All data represent the mean ± SD of three independent 
experiments. *P<0.05 vs. control. (D) DNA fragmentation was detected by in situ TUNEL staining in MES-SA cells after treatment with various concentra-
tions of 15d-PGJ2. Nucleic acids are stained with DAPI (blue). Representative images are shown. Cells were treated with 100 µl DNaseI were included as 
positive controls. (E) Western blot analysis of MES‑SA and MES‑SA/Dx5 cells treated with DMSO (C), 15d‑PGJ2 (P) and relabeling the fig. lanes as C, P, for 
24 h using antibodies against MEK, p‑MEK, ERK, p‑ERK, AKT, and p‑AKT. The band intensities were quantified using the ImageJ software program. The 
presented values were normalized against those of DMSO (C).
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promoted phosphorylation of MAPK. Because of its activation 
of MAPK, the anti-tumor effects of 15d-PGJ2 are limited. 
Recent studies reported ERK-dependent negative feedback in 
several cancers (28). This ERK-dependent negative feedback 
was lost after treatment with a MEK inhibitor, and the ability 
of receptor tyrosine kinase ligands to activate growth signaling 
was markedly enhanced (24,25).
Significant tumor regression may be typical for treatments 
combining PPAR-γ agonists with conventional cytotoxic anti-
cancer agents (15,16). However, the antiproliferative effects 
and mechanism of action of PGJ2 in combination with molec-
ular-targeted agents are unclear. Importantly, our results showed 
that MAPK signaling was activated by 15d-PGJ2. Activation 
of these pathways may limit the antiproliferative effects of 
15d-PGJ2, and thus the addition of molecular-targeted agents 
with PGJ2 may help to suppress these growth pathways.
The orally available TKI dasatinib inhibits SRC, which 
was found to activate receptor tyrosine kinases that induce 
trastuzumab de novo and acquired resistance. This drug is 
currently being examined in cancer patients (20,21) and also 
in several solid tumors (18,22,29,30). Previous studies showed 
that in nasopharyngeal carcinoma treated with dasatinib, 
phospho-AKT, phospho-MEK, and phosphor-ERK levels were 
significantly reduced (31). This suggests that dasatinib exhibits 
Figure 4. Dasatinib enhances the inhibitory effect of 15d-PGJ2 on cell proliferation. (A-C) MES-SA cells were seeded 1 day before treatment with 15d-PGJ2 
(10 µmol/l) and various concentrations of dasatinib, and then cultured for 24 h. WST1 assays were performed to assess cell viability and results were 
normalized to those of cells treated with 15d-PGJ2 (10 µmol/l) alone. (D-F) Cellular apoptosis levels in MES-SA, MES-SA/DX5, and SKN cells treated with 
15d‑PGJ2 (10 µmol/l) and arious concentrations of dasatinib and then cultured for 24 h were quantified using the caspase‑3/7 assay. All data represent the 
mean ± SD of three independent experiments. *P<0.05. (G) Western blot analysis of MES-SA cells treated with DMSO (C), 15d-PGJ2 (10 µmol/l) (P), dasatinib 
(5 µmol/l) (D), or 15d‑PGJ2 (10 µmol/l) combined with dasatinib (5 µmol/l) (P+D) for 24 h using the indicated antibodies. The band intensities were quantified 
using the ImageJ software program. The values were normalized against those of the control.
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antitumor effects in uterine sarcoma by downregulating MAPK 
and AKT pathway activity. SRC phosphorylation was inhibited 
to a higher degree in the dasatinib treatment group compared 
with the control group, and inactivation of both the AKT and 
MAPK pathways was observed in the combination treatment 
group (Fig. 4). This effect of dasatinib appears to be mediated 
by inhibition of SRC phosphorylation. These results showed that 
inhibition of SRC has sustained effects on the MAPK cascade 
and AKT in uterine sarcoma.
Fig. 5 presents a schematic model of the mechanisms of 
15d-PGJ2 and dasatinib in uterine sarcoma cells. The MAPK 
pathway is activated by 15d-PGJ2 treatment, and combined 
treatment with 15d-PGJ2 and dasatinib suppresses both the 
AKT and MAPK pathways, leading to synergistic antiprolifera-
tive effects.
In conclusion, this study demonstrated the tumor-suppressive 
effects and major underlying mechanism of 15d-PGJ2 in uterine 
sarcoma involving inactivation of the AKT pathway. Treatment 
with 15d-PGJ2 combined with dasatinib produced a synergistic 
effect by negatively regulating both AKT and MAPK pathways. 
These results suggest that 15d-PGJ2 could be used in combi-
nation with dasatinib as a potential therapeutic approach for 
uterine sarcoma.
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